Compare Huntington Bancshares Incorporated (HBAN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs ResMed Inc. — how do they compare? Huntington Bancshares Incorporated trades at $18.13 (market cap $36.62B), while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: Huntington Bancshares Incorporated is the larger of the two by market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.43%). Which is the better fit depends on your goals.
| HBAN | RMD | |
|---|---|---|
Market Cap | $36.62B | $28.81B |
Sector | Financials | Health |
52-Week High | $19.27 | $293.73 |
52-Week Low | $15.02 | $182.82 |
Dividend Yield | 3.43% | 1.21% |
Enterprise Value | — | $27.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $18.17, down 0.44% on the day, with a bullish technical signal supported by moving averages. The stock shows a P/E of 13.9 and a net income margin of 25.13%, with Q2 2026 earnings expected at $0.39 per share. Recent news highlights the upcoming earnings report on July 23, 2026, and positive developments from the company's Texas expansion.
The outlook for HBAN is positive, driven by earnings growth potential and analyst consensus of $20.25 price target. Key risks include integration challenges from acquisitions and competitive pressures in regional banking markets. The stock presents a value opportunity with solid fundamentals, though investors should monitor expense management and loan growth trends.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
